Business Acquisition, Contingent Value Right, Additional Price Per Share

No definition available.

Name:	lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare
Namespace Prefix:	lly_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs

+ References

No definition available.

+ Details

Name:	lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
Namespace Prefix:	lly_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development

+ References

No definition available.

+ Details

Name:	lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Disposal Group, Not Discontinued Operation, Payment To Be Received

+ References

No definition available.

+ Details

Name:	lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number Of Medicines, Rights To, Sold

+ References

No definition available.

+ Details

Name:	lly_NumberOfMedicinesRightsToSold
Namespace Prefix:	lly_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of intangible assets, excluding goodwill, acquired at the acquisition date.

+ References

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.

+ References

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

+ Details

Name:	us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266

+ Details

Name:	us-gaap_Goodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow for purchase of marketable security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562

+ Details

Name:	us-gaap_PaymentsToAcquireMarketableSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the cash inflow during the period from the sale of a component of the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585

+ Details

Name:	us-gaap_RepaymentsOfLongTermDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=lly_EddingpharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	lly_AssetAcquisitionAxis=lly_PrecisionBioSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	lly_AssetAcquisitionAxis=lly_MerusNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions and Divestiture (Narrative) (Details) $ / shares in Units, $ in Millions	1 Months Ended				3 Months Ended		11 Months Ended	12 Months Ended
	Jan. 31, 2021 USD ($) $ / shares	Feb. 29, 2020 USD ($)	Oct. 31, 2019 USD ($) medicine	Feb. 28, 2019 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Feb. 15, 2019 USD ($)
Business Acquisition [Line Items]
Acquired IPR&D charges								$ 660.4	$ 239.6	$ 1,980.0
Goodwill						$ 3,679.4	$ 3,679.4	3,766.5	3,679.4
Repayments of long-term debt								276.5	2,866.4	1,009.1
Gain related to disposition								0.0	$ 309.8	$ 0.0
Dermira
Business Acquisition [Line Items]
Consideration transferred		$ 849.3
Goodwill		86.8
Intangibles acquired		1,200.0
Deferred income tax liabilities assumed		49.5
Long-term debt assumed		$ 375.5
Repayments of long-term debt								$ 276.2
Loxo Oncology, Inc.
Business Acquisition [Line Items]
Consideration transferred				$ 6,920.0
Goodwill											$ 2,326.9
Deferred income tax liabilities assumed											1,032.8
Acquired IPR&D											4,670.0
Revenue							$ 136.7
Loxo Oncology, Inc. \| Selpercatinib (LOXO-292)
Business Acquisition [Line Items]
Acquired IPR&D											$ 4,600.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China \| Eddingpharm
Business Acquisition [Line Items]
Number of legacy antibiotic medicines rights sold \| medicine			2
Proceeds from divestiture of businesses, net of cash divested			$ 354.8
Disposal group, not discontinued operation, payment to be received			$ 40.3
Gain related to disposition						$ 309.8
Subsequent Event \| Precision BioSciences, Inc.
Business Acquisition [Line Items]
Payments for acquisitions	$ 100.0
Consideration transferred, equity interests purchased	35.0
Subsequent Event \| Merus N.V.
Business Acquisition [Line Items]
Payments for acquisitions	40.0
Consideration transferred, equity interests purchased	20.0
Subsequent Event \| Forecast \| Precision BioSciences, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges					$ 107.8
Subsequent Event \| Forecast \| Merus N.V.
Business Acquisition [Line Items]
Acquired IPR&D charges					46.5
Subsequent Event \| Prevail Therapeutics Inc.
Business Acquisition [Line Items]
Payments for acquisitions	$ 880.0
Business acquisition, share price (in dollars per share) \| $ / shares	$ 22.50
Contingent value right, additional price per share (in dollars per share) \| $ / shares	$ 4.00
Contingent value right, additional price per share, aggregate amount	$ 160.0
Contingent value right, monthly reduction \| $ / shares	$ 0.083
Subsequent Event \| Asahi Kasei Pharma Corporation \| Forecast
Business Acquisition [Line Items]
Acquired IPR&D charges					$ 20.0